Drug Trial Radar · NCT06810791
HVA vs IA/DA or VA in the Treatment of ND HR-AML
Last checked: Nov 19, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
876
Planned (sponsor's estimate)
Start
Jan 1, 2025
Primary completion
Jun 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Guangzhou First People's Hospital; Guangdong Second Provincial General Hospital; Jiangmen Central Hospital; Shenzhen Second People's Hospital; First Affiliated Hospital of Guangxi Medical University; Dongguan People's Hospital; First People's Hospital of Foshan; Guangdong Provincial Hospital of Traditional Chinese Medicine; Huizhou Municipal Central Hospital; Shenzhen Hospital of Southern Medical University; Affiliated Hospital of Guangdong Medical University; People's Hospital of Guangxi Zhuang Autonomous Region; First People's Hospital of Chenzhou; Hunan Provincial People's Hospital; Ganzhou City People's Hospital; First Affiliated Hospital of Gannan Medical University
- First posted
- Feb 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed high-risk AML patients.
Conditions
- Newly Diagnosed Acute Myeloid Leukemia With High Risk
Interventions
HVADrug
Homoharringtonine (HHT) is given by venous drip daily at 1 mg/m2 from day 1 to 7. Venetoclax (VEN) is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 14. Azacitidine (AZA) is given 75 mg/m2 subcutaneously from day 1 to 7.
VADrug
VEN is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 28, and AZA (75 mg/m2) is given subcutaneously from day 1 to 7.
Standard ChemotherapyDrug
Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine). IDA is given by venous drip daily at 12mg/m2, or DNR is given by venous drip daily at 60mg/m2, from day 1-3, combined with Ara-C at 100mg/m2 by continuously venous drip from day 1-7.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite complete remission (CRc)Time frame: At the end of cycle 2 (each cycle is 28 days).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.